EXPERIMENTAL HEMATOLOGY

Scope & Guideline

Empowering Discoveries in Blood and Cellular Biology

Introduction

Delve into the academic richness of EXPERIMENTAL HEMATOLOGY with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN0301-472x
PublisherELSEVIER SCIENCE INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1973 to 2024
AbbreviationEXP HEMATOL / Exp. Hematol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressSTE 800, 230 PARK AVE, NEW YORK, NY 10169

Aims and Scopes

EXPERIMENTAL HEMATOLOGY focuses on advancing the understanding of hematopoiesis, hematological malignancies, and related therapeutic interventions. The journal emphasizes innovative research methodologies and interdisciplinary approaches to address key challenges in the field.
  1. Hematopoiesis and Stem Cell Biology:
    The journal covers extensive research on the mechanisms of hematopoiesis, including the development, differentiation, and function of hematopoietic stem cells (HSCs), progenitor cells, and their niches.
  2. Hematological Malignancies:
    Research on the molecular and cellular basis of hematological cancers, including leukemias, lymphomas, and myeloproliferative neoplasms, is a core area of focus, particularly mechanisms of tumorigenesis and therapeutic resistance.
  3. Therapeutic Innovations:
    EXPERIMENTAL HEMATOLOGY publishes studies on novel therapeutic strategies, including gene therapy, immunotherapy, and targeted treatments for hematological diseases, highlighting translational research.
  4. Microenvironment and Niche Interactions:
    The journal emphasizes the role of the bone marrow microenvironment and other niches in regulating hematopoietic cell behavior, interactions between different cell types, and their impact on disease.
  5. Epigenetics and Transcriptional Regulation:
    Research exploring the epigenetic landscape and transcriptional control mechanisms governing hematopoietic development and malignancies is prominently featured, reflecting the journal's commitment to understanding gene regulation.
  6. Systemic and Local Regulation of Hematopoiesis:
    Studies addressing the systemic factors influencing hematopoiesis and the local signals from the microenvironment that modulate hematopoietic function are integral to the journal's scope.
EXPERIMENTAL HEMATOLOGY is currently witnessing several emerging themes that reflect the cutting-edge advancements in hematology research. These trends indicate a shift towards more innovative methodologies and interdisciplinary approaches.
  1. Single-Cell Technologies:
    An increasing number of studies are employing single-cell RNA sequencing and other single-cell technologies to elucidate the heterogeneity of hematopoietic stem and progenitor cells, providing insights into their function and regulation.
  2. Metabolic Regulation:
    Research focusing on the metabolic pathways that influence hematopoietic stem cell function and differentiation is gaining prominence, highlighting the interplay between metabolism and cell fate.
  3. Inflammation and Immune Interactions:
    The role of inflammation and immune responses in regulating hematopoiesis and hematological malignancies is an emerging theme, with studies investigating how these factors influence disease progression.
  4. Gene Editing and Genetic Models:
    There is a notable increase in studies utilizing advanced gene editing techniques (e.g., CRISPR/Cas9) to model hematological diseases and explore genetic factors contributing to malignancies.
  5. Epitranscriptomics:
    The exploration of RNA modifications (e.g., m6A methylation) and their impact on gene expression and hematopoietic function is an emerging area of interest, reflecting the evolving understanding of post-transcriptional regulation.
  6. Therapeutic Targeting of the Microenvironment:
    Research targeting the bone marrow microenvironment to enhance hematopoietic stem cell recovery and improve treatment outcomes in hematological malignancies is gaining traction, indicating a shift towards niche-focused therapies.

Declining or Waning

While EXPERIMENTAL HEMATOLOGY continues to thrive in many areas, certain themes appear to be waning or experiencing decreased publication frequency. This could reflect shifts in research focus or advances in understanding that render some topics less prominent.
  1. Traditional Animal Models:
    Research utilizing conventional animal models for hematopoiesis and leukemia studies is less frequently published, potentially due to the increasing adoption of advanced in vitro and humanized models.
  2. Basic Hematology without Translational Focus:
    Papers focusing solely on basic hematological research without clear translational implications are becoming less common, as the field increasingly emphasizes studies that bridge basic science with clinical application.
  3. Single-Agent Therapeutic Studies:
    The publication of studies focusing exclusively on single-agent therapies without exploring combination strategies or innovative approaches appears to be declining, reflecting a shift towards more complex treatment paradigms.
  4. Epidemiological Studies:
    There has been a noticeable decrease in the publication of epidemiological studies related to hematological disorders, possibly due to a growing emphasis on mechanistic and experimental research.

Similar Journals

CURRENT OPINION IN HEMATOLOGY

Bridging research and application in the realm of hematology.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1065-6251Frequency: 6 issues/year

CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.

Cell Discovery

Empowering Open Access to Cutting-Edge Research
Publisher: SPRINGERNATUREISSN: Frequency: 1 issue/year

Cell Discovery, published by SPRINGERNATURE, is a premier open access journal in the dynamic fields of Biochemistry, Cell Biology, Genetics, and Molecular Biology. Since its inception in 2015, this journal has established itself as a key platform for disseminating high-impact research and is recognized with a Q1 ranking across all its core categories for the year 2023. With its remarkable Scopus rankings—7th in Genetics, 9th in Biochemistry, 13th in Molecular Biology, and 15th in Cell Biology—Cell Discovery positions itself among the elite journals in life sciences, showcasing the most innovative breakthroughs and comprehensive reviews. Based in the United Kingdom, this journal operates under an open access model, ensuring that groundbreaking discoveries are readily available to researchers, professionals, and students around the globe. With a commitment to advancing scientific knowledge, Cell Discovery welcomes contributions that push the frontiers of our understanding in cellular and genetic sciences.

Molecular Cell

Where Innovative Research Meets Cellular Insight.
Publisher: CELL PRESSISSN: 1097-2765Frequency: 24 issues/year

Molecular Cell, published by Cell Press, is a leading journal in the fields of cell biology and molecular biology. Established in 1997, this prestigious journal boasts a significant impact within the scientific community, evidenced by its impressive 2023 Scopus rankings, placing it in the top 2% of its field (Rank #10/410 in Molecular Biology, Rank #12/285 in Cell Biology). With a focus on cutting-edge research that bridges the gap between molecular genetics and cellular function, Molecular Cell serves as an essential platform for the dissemination of vital findings and innovative methodologies. Although it follows a traditional publishing model without Open Access options, its rigorous peer-review process and high standards ensure that articles published within these pages are of the utmost quality, making it an invaluable resource for researchers, professionals, and students alike seeking to stay at the forefront of scientific discovery. The journal's address is 50 Hampshire St, Floor 5, Cambridge, MA 02139, United States, reinforcing its commitment to fostering scientific excellence and collaboration.

Turkish Journal of Hematology

Connecting researchers and clinicians to elevate hematology practices.
Publisher: GALENOS PUBL HOUSEISSN: 1300-7777Frequency: 4 issues/year

Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.

Hematologie

Connecting Researchers and Clinicians in Hematology
Publisher: JOHN LIBBEY EUROTEXT LTDISSN: 1264-7527Frequency: 6 issues/year

Hematologie is a highly regarded journal in the field of hematology, published by JOHN LIBBEY EUROTEXT LTD. With an ISSN of 1264-7527 and an E-ISSN of 1950-6368, this journal has established itself as a vital resource for researchers, clinicians, and students dedicated to advancing the understanding of blood disorders and treatments. Although the journal's coverage in Scopus was discontinued in 2018, it has continually provided invaluable insights and research findings. The journal aims to foster knowledge sharing and discussion in hematology, exploring innovative methodologies and emerging trends in the field. With a commitment to quality research, Hematologie remains an essential platform for disseminating critical findings that can drive clinical practice and influence future studies in hematological sciences.

Advances in Cancer Biology-Metastasis

Connecting Research to Real-World Impact.
Publisher: ELSEVIERISSN: Frequency: 4 issues/year

Advances in Cancer Biology-Metastasis is an emerging journal published by Elsevier, aimed at advancing our understanding of the complexities of cancer biology, with a specific focus on the mechanisms and pathways related to metastasis. With an E-ISSN of 2667-3940, this journal offers a platform for researchers, professionals, and students in the fields of Cancer Research and Cell Biology to disseminate innovative findings and discuss novel therapeutic approaches. Though currently classified in the Q4 quartile across both Cancer Research and Cell Biology categories, the journal aspires to enhance its impact through rigorous peer review and high-quality publication. Positioned to cover the years from 2021 to 2024, it seeks to bridge gaps in foundational knowledge and promote collaborative research efforts that could pivot the current understanding of cancer metastasis. Researchers are encouraged to take advantage of this platform to advocate for advancements in cancer biology, making significant contributions that can influence both academic and clinical practices.

Therapeutic Advances in Hematology

Transforming research into impactful therapies.
Publisher: SAGE PUBLICATIONS LTDISSN: 2040-6207Frequency: 1 issue/year

Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.

CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION

Advancing the Frontiers of Gene Expression Knowledge
Publisher: BEGELL HOUSE INCISSN: 1045-4403Frequency: 3 issues/year

CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, published by BEGELL HOUSE INC, serves as a vital resource within the fields of Genetics and Molecular Biology. With the ISSN 1045-4403 and E-ISSN 2162-6502, this journal has been contributing to scientific discourse since 1990 and is projected to continue its publication until 2024. Despite its classification in the Q3 quartile for both Genetics and Molecular Biology, its impact on the research community is significant, as evidenced by its diverse range of critical reviews that synthesize and analyze emerging trends and foundational studies in gene expression. The journal, located in the United States at 50 North St, Danbury, CT 06810, offers a platform for researchers, professionals, and students to engage with innovative ideas and methodologies that drive forward the understanding of gene regulatory mechanisms in eukaryotes. Although it currently does not offer open access, the journal's content remains crucial for those dedicated to advancing knowledge in the intricacies of genetic expression.

BLOOD CELLS MOLECULES AND DISEASES

Advancing Knowledge in Hematology and Molecular Biology
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCEISSN: 1079-9796Frequency: 6 issues/year

BLOOD CELLS MOLECULES AND DISEASES is a prominent multidisciplinary journal published by Academic Press Inc., Elsevier Science, specializing in the fields of hematology, molecular biology, and cell biology. With an ISSN of 1079-9796 and an E-ISSN of 1096-0961, this journal serves as a vital resource for researchers, professionals, and students exploring the complex interplay between blood cells and their corresponding molecular pathways in disease states. Spanning topics from cellular mechanisms to therapeutic advancements, BLOOD CELLS MOLECULES AND DISEASES holds a commendable reputation with a 2023 category quartile ranking of Q2 in Hematology and Q3 in several related fields. This journal not only provides a platform for the dissemination of innovative research but also fosters collaboration and knowledge exchange within the scientific community. As it converges from 1995 to 2025, the journal continues to impact the medical and biological sciences significantly, making it an essential tool for advancing our understanding of hematologic diseases.

BIOCELL

Pioneering Discoveries in Molecular Biology
Publisher: TECH SCIENCE PRESSISSN: 0327-9545Frequency: 12 issues/year

BIOCELL is a distinguished peer-reviewed journal dedicated to the field of Cell Biology, published by TECH SCIENCE PRESS. Since its inception in 1995, the journal has been at the forefront of disseminating innovative research, with converged publication years extending from 1995 to 2013 and from 2015 to 2024. Although it currently holds a Q4 ranking in the Cell Biology category according to the 2023 category quartiles, BIOCELL aims to foster advancements by providing a platform for researchers, professionals, and students to share their findings in biochemistry, genetics, and molecular biology. The journal is available in both print (ISSN: 0327-9545) and digital formats (E-ISSN: 1667-5746) and seeks to attract contributions that enhance scholarly dialogue and understandings of cellular mechanisms and innovations. With a commitment to quality research and critical discourse, BIOCELL plays an important role in nurturing the scientific community within Argentina and beyond, offering vital insights that contribute to the advancement of the life sciences.